Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2017

01.04.2017 | Epidemiology

Adherence to guidelines and breast cancer patients survival: a population-based cohort study analyzed with a causal inference approach

verfasst von: Anita Andreano, Paola Rebora, Maria Grazia Valsecchi, Antonio Giampiero Russo

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

There is a lack of real-world studies evaluating the impact on survival of an evidence-based pathway of care in breast cancer. The aim of this work is to investigate the effect of adherence to guidelines on long-term survival for a cohort of Italian breast cancer patients.

Methods

The cohort included incident female breast cancer cases (2007–12), from the registry of the Milan province (Italy), not metastatic at diagnosis and receiving primary surgery. We selected sets of indicators, according to patient and tumor characteristics. We then defined the pathway of care as adherent to guidelines if it fulfilled at least 80% of the indicators. Indicators were measured using different administrative health databases linked on a unique key. A causal inference approach was used, drawing a directed acyclic graph and fitting an inverse probability weighted marginal structural model, accounting for patient’s demographic, socioeconomic and tumor characteristics.

Results

The analysis included 6333 patients, 69% of them were classified as having an adherent care. Mean age was 61 years (standard deviation, 13.6 years) and half of the patients were in Stage I (50%) at diagnosis. Median follow-up time was 5.6 years. Overall, 5-year survival was 90% (95% CI, 89–91%). The estimated risk of death was 30% lower for patients with adherent than nonadherent care (hazard ratio [HR], 0.66; 95% CI, 0.55–0.77).

Conclusions

Our study confirms, in real-world care, the impact on survival of receiving a care pathway adherent to guidelines in non-metastatic breast cancer patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
4.
Zurück zum Zitat Brouwers MC, Kho ME, Browman GP et al (2010) AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ Can Med Assoc J 182:E839–E842. doi:10.1503/cmaj.090449 CrossRef Brouwers MC, Kho ME, Browman GP et al (2010) AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ Can Med Assoc J 182:E839–E842. doi:10.​1503/​cmaj.​090449 CrossRef
6.
Zurück zum Zitat Mehta RH, Chen AY, Alexander KP et al (2015) Doing the right things and doing them the right way: association between hospital guideline adherence, dosing safety, and outcomes among patients with acute coronary syndrome. Circulation 131:980–987. doi:10.1161/CIRCULATIONAHA.114.013451 CrossRefPubMed Mehta RH, Chen AY, Alexander KP et al (2015) Doing the right things and doing them the right way: association between hospital guideline adherence, dosing safety, and outcomes among patients with acute coronary syndrome. Circulation 131:980–987. doi:10.​1161/​CIRCULATIONAHA.​114.​013451 CrossRefPubMed
10.
Zurück zum Zitat Boland GM, Chang GJ, Haynes AB et al (2013) Association between adherence to national comprehensive cancer network treatment guidelines and improved survival in patients with colon cancer: guideline treatment improves survival. Cancer 119:1593–1601. doi:10.1002/cncr.27935 CrossRefPubMed Boland GM, Chang GJ, Haynes AB et al (2013) Association between adherence to national comprehensive cancer network treatment guidelines and improved survival in patients with colon cancer: guideline treatment improves survival. Cancer 119:1593–1601. doi:10.​1002/​cncr.​27935 CrossRefPubMed
11.
Zurück zum Zitat van de Water W, Bastiaannet E, Dekkers OM et al (2012) Adherence to treatment guidelines and survival in patients with early-stage breast cancer by age at diagnosis. Br J Surg 99:813–820. doi:10.1002/bjs.8743 CrossRefPubMed van de Water W, Bastiaannet E, Dekkers OM et al (2012) Adherence to treatment guidelines and survival in patients with early-stage breast cancer by age at diagnosis. Br J Surg 99:813–820. doi:10.​1002/​bjs.​8743 CrossRefPubMed
12.
Zurück zum Zitat Feinstein AR (1985) Clinical epidemiology: the architecture of clinical research. Saunders, Philadelphia Feinstein AR (1985) Clinical epidemiology: the architecture of clinical research. Saunders, Philadelphia
20.
Zurück zum Zitat Meiers P, Cil T, Guller U, Zuber M (2013) Sentinel lymph node biopsy in early-stage breast cancer patients: improved survival through better staging? Langenbecks Arch Surg Dtsch Ges Für Chir 398:687–690. doi:10.1007/s00423-012-1037-2 CrossRef Meiers P, Cil T, Guller U, Zuber M (2013) Sentinel lymph node biopsy in early-stage breast cancer patients: improved survival through better staging? Langenbecks Arch Surg Dtsch Ges Für Chir 398:687–690. doi:10.​1007/​s00423-012-1037-2 CrossRef
21.
23.
Zurück zum Zitat A’Hern RP, Ebbs SR, Baum MB (1988) Does chemotherapy improve survival in advanced breast cancer? A statistical overview. Br J Cancer 57:615–618CrossRefPubMedPubMedCentral A’Hern RP, Ebbs SR, Baum MB (1988) Does chemotherapy improve survival in advanced breast cancer? A statistical overview. Br J Cancer 57:615–618CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. The Lancet 378:771–784. doi:10.1016/S0140-6736(11)60993-8 CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. The Lancet 378:771–784. doi:10.​1016/​S0140-6736(11)60993-8 CrossRef
26.
Zurück zum Zitat Clarke M, Collins R, Darby S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366:2087–2106. doi:10.1016/S0140-6736(05)67887-7 CrossRefPubMed Clarke M, Collins R, Darby S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366:2087–2106. doi:10.​1016/​S0140-6736(05)67887-7 CrossRefPubMed
28.
30.
Zurück zum Zitat Greenland S, Pearl J, Robins JM (1999) Causal diagrams for epidemiologic research. Epidemiol Camb Mass 10:37–48CrossRef Greenland S, Pearl J, Robins JM (1999) Causal diagrams for epidemiologic research. Epidemiol Camb Mass 10:37–48CrossRef
32.
Zurück zum Zitat Andreano A, Anghinoni E, Autelitano M et al (2016) Indicators based on registers and administrative data for breast cancer: routine evaluation of oncologic care pathway can be implemented. J Eval Clin Pract 22:62–70. doi:10.1111/jep.12436 CrossRefPubMed Andreano A, Anghinoni E, Autelitano M et al (2016) Indicators based on registers and administrative data for breast cancer: routine evaluation of oncologic care pathway can be implemented. J Eval Clin Pract 22:62–70. doi:10.​1111/​jep.​12436 CrossRefPubMed
33.
Zurück zum Zitat Quan H, Li B, Couris CM et al (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173:676–682. doi:10.1093/aje/kwq433 CrossRefPubMed Quan H, Li B, Couris CM et al (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173:676–682. doi:10.​1093/​aje/​kwq433 CrossRefPubMed
35.
Zurück zum Zitat Caranci N, Biggeri A, Grisotto L et al (2010) L’indice di deprivazione italiano a livello di sezione di censimento: definizione, descrizione e associazione con la mortalità. Epidemiol Prev 34:167PubMed Caranci N, Biggeri A, Grisotto L et al (2010) L’indice di deprivazione italiano a livello di sezione di censimento: definizione, descrizione e associazione con la mortalità. Epidemiol Prev 34:167PubMed
37.
Zurück zum Zitat Hernán M, Robins JM (2017) Causal survival analysis. In: Causal Inference. Chapman & Hall/CRC, Boca Raton, partII, pp 75–77 Hernán M, Robins JM (2017) Causal survival analysis. In: Causal Inference. Chapman & Hall/CRC, Boca Raton, partII, pp 75–77
39.
Zurück zum Zitat Rubin DB (2004) Multiple imputation for nonresponse in surveys. John Wiley & Sons, Hoboken Rubin DB (2004) Multiple imputation for nonresponse in surveys. John Wiley & Sons, Hoboken
40.
Zurück zum Zitat SAS Institute Inc. (2013) SAS/STAT Software, Version 9.4., Cary, NC SAS Institute Inc. (2013) SAS/STAT Software, Version 9.4., Cary, NC
41.
Zurück zum Zitat Core Team R (2015) R: A Language and Environment for Statistical Computing. R Found Stat Computing, Vienna, Austria Core Team R (2015) R: A Language and Environment for Statistical Computing. R Found Stat Computing, Vienna, Austria
42.
Zurück zum Zitat Steuten L, Vrijhoef B, Severens H et al (2006) Are we measuring what matters in health technology assessment of disease management? Systematic literature review. Int J Technol Assess Health Care 22:47–57. doi:10.1017/S0266462306050835 CrossRefPubMed Steuten L, Vrijhoef B, Severens H et al (2006) Are we measuring what matters in health technology assessment of disease management? Systematic literature review. Int J Technol Assess Health Care 22:47–57. doi:10.​1017/​S026646230605083​5 CrossRefPubMed
Metadaten
Titel
Adherence to guidelines and breast cancer patients survival: a population-based cohort study analyzed with a causal inference approach
verfasst von
Anita Andreano
Paola Rebora
Maria Grazia Valsecchi
Antonio Giampiero Russo
Publikationsdatum
01.04.2017
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2017
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4210-z

Weitere Artikel der Ausgabe 1/2017

Breast Cancer Research and Treatment 1/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.